J Sex Med. 2006 Sep;3(5):910-7.
El-Shafey H, Atteya A, el-Magd SA, Hassanein A,
Fathy A, Shamloul R.
Department of Andrology, Sexology and STDs, Cairo
University, New Maadi, Cairo, Egypt.
dysfunction (ED) and depression are highly prevalent medical
disorders affecting men of diverse cultures throughout the world.
Tianeptine is a new antidepressant drug with less adverse effects on
AIM: To evaluate the
efficacy of tianeptine in the treatment of mild to moderate
depression with ED.
METHODS AND MAIN OUTCOME
MEASURES: A randomized, double-blind, placebo-controlled,
crossover trial. Subjects were assigned either tianeptine or
matching placebo, each for 8 weeks. All patients were followed up on
monthly basis where they were asked to complete three assessment
questionnaires, namely, Anxiety and Depression Scale, Brief Sexual
Inventory, and Quality-of-life and erection questionnaire. All
patients were asked a global assessment question.
Treatment-responsive subjects were defined as study participants who
had scores 1-16 on the Anxiety and depression Scale, showed normal
erectile function on the Brief Sexual Inventory, and answered "yes"
to the global assessment question.
RESULTS: Of the 237
consecutive men complaining of ED of >6 months and screened for this
study, 110 patients met our inclusive criteria; 42 declined to
participate. The remaining 68 patients were randomly assigned to
treatment. Significant improvement (P < 0.05) was observed during
the active drug phase in all three assessments questionnaires, in
comparison with the placebo phase. Forty-eight patients (72.7%) of
the subjects during the active drug phase were classified as
responders, while 19 (27.9%) of the subjects during placebo phase
were classified as responders.
could be considered an effective therapy for the treatment of
depression and ED. Further large-scale multicentered studies are